


## PD-1/PD-L1-IN-13

<b>Cat. No.:</b>	HY-145239		
<b>CAS No.:</b>	2865841-81-0		
<b>Molecular Formula:</b>	C <sub>36</sub> H <sub>34</sub> ClF <sub>2</sub> N <sub>3</sub> O <sub>9</sub>		
<b>Molecular Weight:</b>	726.12		
<b>Target:</b>	PD-1/PD-L1		
<b>Pathway:</b>	Immunology/Inflammation		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 150 mg/mL (206.58 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.3772 mL	6.8859 mL	13.7718 mL
	5 mM	0.2754 mL	1.3772 mL	2.7544 mL
	10 mM	0.1377 mL	0.6886 mL	1.3772 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 3.75 mg/mL (5.16 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 3.75 mg/mL (5.16 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 3.75 mg/mL (5.16 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC<sub>50</sub> value of 10.2 nM. PD-1/PD-L1-IN-13 promotes CD8<sup>+</sup> T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model<sup>[1]</sup>.

### REFERENCES

---

[1]. Song Z, et al. Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage. J Med Chem. 2021;64(22):16687-16702.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA